Guardant to Fundamentally Change Mortality Curves in Cancer, CEO Says

10/05/2018 | 7 min | NOT-RATED
Oct.05 -- Guardant Health Inc., a cancer-detection firm backed by SoftBank Group Corp., raised $237.5 million in its U.S. initial public offering. Bloomberg's Alex Barinka talks with Helmy Eltoukhy, chief executive officer and co-founder of Guardant, about the company's business model and growth opportunities.